RDInvesting Provides Investors with Free In-Depth Equity Reports on CLS, CSII, HAE and MNTA
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Celestica Inc. (NYSE: CLS)(TSX: CLS) shares increased 6.20 percent to close at $10.11 a share Friday. The stock traded between $9.63 and $10.41 on volume of 991,110 shares traded. Analysts at Raymond James have recently upgraded the company’s rating to “outperform” from “market perform”. Shares of Celestica have gained approximately 24.0 percent year-to-date.
Find out more about Celestica including full access to the free equity report at:
www.RDInvesting.com/CLS
Cardiovascular Systems Inc. (NASDAQ: CSII) shares increased 0.53 percent to close at $20.90 a share Friday. The stock traded between $20.59 and $21.25 on volume of 129,469 shares traded. Analysts at Wunderlich have recently initiated coverage on the company with a “buy” rating. Shares of Cardiovascular Systems have gained approximately 66.5 percent year-to-date.
Find out more about Cardiovascular Systems including full access to the free equity report at:
www.RDInvesting.com/CSII
Haemonetics Corporation (NYSE: HAE) shares declined 0.83 percent to close at $45.43 a share Thursday. The stock traded between $45.09 and $45.57 on volume of 209,886 shares traded. Analysts at Alere Financial have recently initiated coverage on the company with a “buy” rating. Shares of Haemonetics have gained approximately 62.5 percent year-to-date.
Find out more about Haemonetics including full access to the free equity report at:
www.RDInvesting.com/HAE
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) shares surged 11.73 percent to close at $17.34 a share Friday. The stock traded between $15.28 and $18.08 on volume of 4.08 million shares traded. Analysts at Canaccord have recently upgraded the company’s rating to “buy” from “hold”. Shares of Momenta Pharmaceuticals have gained approximately 47.0 percent year-to-date.
Find out more about Momenta Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/MNTA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com